Search clinical trials for: Orkambi

Total 13 results

Societe Francaise de la Mucoviscidose

Recruiting

Response to CFTR Modulators in CF Patients Under 18 Years (MODUL-CF)

Cystic Fibrosis in Children

France
Children's Hospital of Philadelphia
Vertex Pharmaceuticals Incorporated

Completed

Orkambi Treatment in 2 to 5 Year Old Children With CF

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
University Hospital, Antwerp

Terminated

Functional Respiratory Imaging and Orkambi in CF

Cystic Fibrosis

Belgium
Istituto Auxologico Italiano

Recruiting

Mutation-specific Therapy for the Long QT Syndrome (MAST2)

Long QT Syndrome

Italy
Assistance Publique - Hôpitaux de Paris

Completed

Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®. (PREDICT-CF)

Cystic Fibrosis | Homozygous F508del Mutation

France
University of Alabama at Birmingham

Recruiting

Personalized Theratyping Trial

Cystic Fibrosis

United States
Assistance Publique - Hôpitaux de Paris
Societe Francaise de la Mucoviscidose; Effi-Stat

Completed

Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*) (ORKAMBI)

Cystic Fibrosis

France
Massachusetts General Hospital

Terminated

The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia

Diabetes | Cystic Fibrosis
Carmel Medical Center

Completed

Real Life Evaluation of the Multi-organ Effects of Lumacaftor/Ivacaftor on F508del Homozygous Cystic Fibrosis Patients.

Cystic Fibrosis
Hannover Medical School
Heidelberg University; University of Giessen

Completed

ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor (OrkambiFacts)

Cystic Fibrosis

Germany
Massachusetts General Hospital

Withdrawn

Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del (LIGHT-CF)

Diabetes | Cystic Fibrosis
Parion Sciences
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United Kingdom, United States, France, Ireland

Search clinical trials for: Orkambi

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations